BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong
CAMBRIDGE, Mass., and BEIJING, China, Feb. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will hold a fourth quarter and full year 2018 financial results conference call and webcast on Wednesday, February 27, 2019, at 6:00 p.m. ET. On the call, Company management will provide an overview of BeiGene’s financial results for the fourth quarter and full year 2018, and updates on recent business highlights and upcoming milestones.
BeiGene will also host an in-person and webcast investor event in Hong Kong on Thursday, February 28, at 2:30 – 4:00 p.m. HKT (Thursday, February 28, at 1:30 – 3:00 a.m. ET) at the Island Shangri-La Hong Kong.
Financial Results Conference Call and Webcast InformationInvestors and analysts are invited to join the conference call using the following dial-in information:U.S. Toll-Free: (844) 461-9930 Hong Kong: 3011-4522China: 400-682-8609Conference ID: 8889396
A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ or http://hkexir.beigene.com. An archived replay will be available two hours after the event for 90 days.
Hong Kong Investor Event, Conference Call and Webcast InformationHong Kong Investor EventDate and Time: Thursday, February 28, at 2:30 p.m. HKT (Thursday, February 28, at 1:30 a.m. ET)Location: Island Shangri-La, Hong Kong, Level 5, Ballroom A
A live webcast of the investor event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ or http://hkexir.beigene.com. An archived replay will be available two hours after the event for 90 days.
About BeiGeneBeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
U.S. Investor Contact U.S. Media Contact Craig West Liza Heapes +1 857-302-5189 +1 857-302-5663 firstname.lastname@example.org email@example.com China Investor Contact China Media Contact Gabrielle Zhou Lei Lyu +86 10-5895-8058 +86 10-5895-8049 firstname.lastname@example.org email@example.com
______________________________i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.